Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen Macarena (16)

2024

  1. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Impact of the “Zero Resistance” program on acquisition of multidrug-resistant bacteria in patients admitted to Intensive Care Units in Spain. A prospective, intervention, multimodal, multicenter study

    Medicina Intensiva, Vol. 47, Núm. 4, pp. 193-202

2022

  1. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2019

  1. Clinical and molecular diagnosis of non-phosphomannomutase 2 N-linked congenital disorders of glycosylation in Spain

    Clinical Genetics, Vol. 95, Núm. 5, pp. 615-626

  2. Treatment outcome in dually HIV-1 and HIV-2 coinfected patients living in Spain

    AIDS, Vol. 33, Núm. 14, pp. 2167-2172

2013

  1. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

2012

  1. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-for the treatment of chronic hepatitis C in HIV-infected patients: The PERICO trial

    Journal of Infectious Diseases, Vol. 206, Núm. 6, pp. 961-968

2008

  1. Antiretroviral-associated portal hypertension: A new clinical condition? Prevalence, predictors and outcome

    Antiviral Therapy, Vol. 13, Núm. 1, pp. 103-107

  2. Efficacy of pegylated interferon plus ribavirin treatment in HIV/ hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone

    Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 6, pp. 1365-1373

  3. Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy

    AIDS Research and Human Retroviruses, Vol. 24, Núm. 7, pp. 935-940

  4. Profile of patients triply infected with HIV and the hepatitis B and C viruses in the HAART era

    AIDS Research and Human Retroviruses, Vol. 24, Núm. 5, pp. 679-683

2006

  1. Severe liver disease associated with prolonged exposure to antiretroviral drugs

    Journal of Acquired Immune Deficiency Syndromes, Vol. 42, Núm. 2, pp. 177-182

2005

  1. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: Final results of the EFADITE trial

    Antiviral Therapy, Vol. 10, Núm. 7, pp. 825-832

2003

  1. Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients

    Journal of Clinical Microbiology, Vol. 41, Núm. 9, pp. 4421-4423

1997

  1. A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients

    Journal of Infection, Vol. 35, Núm. 3, pp. 225-230